Lundbeck and Otsuka`s brexpiprazole for adult patients with schizophrenia accepted for review by EMA
(WorldNews Denmark)

The European Medicines Agency (EMA) is expected to complete its review in second quarter of 2018. In both short-term and long-term clinical trials involving more than 3,000 patients, brexpiprazole has shown improvement in symptoms of schizophrenia and was generally well-tolerated in adult patients. Valby, 2017-03-23 14:00 CET (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the European Medicines Agency (EMA) has accepted for review a Marketing Authorisation Application for brexpiprazole to treat schizophrenia in adults. Brexpiprazole is a once-daily, second-generation (atypical) oral antipsychotic that was discovered by Otsuka...